SCHEMBL7259697

SCHEMBL7259697

Clc1nc(-c2ccccc2)cc2ccncc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MEN1 O00255 3/20 0.47
ALDH1A1 P00352 3/20 0.47
KMT2A Q03164 3/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP19A1 P11511 1/20 0.45
MAPK10 P53779 1/20 0.44
KDM4E B2RXH2 4/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
RAD52 P43351 1/20 0.44
ALOX5 P09917 1/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31388225 0.80 MEN1 (0.55) L3MBTL1MEN1ALDH1A1KMT2AHPGD
SCHEMBL786133 0.80 MEN1 (0.55) L3MBTL1MEN1ALDH1A1KMT2AHPGD
SCHEMBL4772977 0.80 NPC1 (0.47) MEN1ALDH1A1KMT2AHPGDKDM4E
SCHEMBL6634946 0.80 KDM4E (0.51) TNFMEN1ALDH1A1KMT2AHPGD
SCHEMBL7260213 0.80 IDO1 (0.47) TNFMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL22201436 0.79 PRKCH (0.52) L3MBTL1MEN1ALDH1A1KMT2AHPGD
SCHEMBL14727429 0.79 CYP11B1 (0.57) ALDH1A1KMT2ACYP19A1KDM4EHTT
SCHEMBL24622584 0.77 MAPK10 (0.59) TNFALDH1A1HPGDCYP19A1MAPK10
SCHEMBL3325621 0.76 PRKCD (0.52)
SCHEMBL15124692 0.75 MEN1 (0.53) L3MBTL1MEN1ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337534-A1 3-SUBSTITUTED 2,7-NAPHTHYRIDIN-1-YL DERIVATIVES Celltech R & D Limited (GB) 2003-08-27 EP disclosed
US-6593338-B2 Inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells. CELLTECH R&D LIMITED (GB) 2003-07-15 US disclosed
US-20020137935-A1 3-Substituted 2,7-naphthyridin-1-yl derivatives CELLTECH R&D LIMITED (GB) 2002-09-26 US disclosed
WO-2002042264-A1 3-SUBSTITUTED 2,7-NAPHTHYRIDIN-1-YL DERIVATIVES CELLTECH R & D LIMITED (GB) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137935-A1 3-Substituted 2,7-naphthyridin-1-yl derivatives ITGB2, ICAM1, ITGB1 TNF 2214/4885L3MBTL1 524/4885MEN1 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.